Drugs / ALD1910
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04197349 | Sep 2019 → Aug 2020 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALD1910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04197349 ↗ |
| Modality | Monoclonal antibody | “ALD1910, a monoclonal antibody” NCT04197349 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT04197349 ↗ |